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Abstract
Prenatal exposure to allergens or antigens released by infections during pregnancy can stimulate an immune response or
induce immunoregulatory networks in the fetus affecting susceptibility to infection and disease later in life. How antigen
crosses from the maternal to fetal environment is poorly understood. One hypothesis is that transplacental antigen transfer
occurs as immune complexes, via receptor-mediated transport across the syncytiotrophoblastic membrane and
endothelium of vessels in fetal villi. This hypothesis has never been directly tested. Here we studied Plasmodium
falciparum merozoite surface protein 1 (MSP1) that is released upon erythrocyte invasion. We found MSP1 in cord blood
from a third of newborns of malaria-infected women and in .90% following treatment with acid dissociation
demonstrating MSP1 immune complexes. Using an ex vivo human placental model that dually perfuses a placental
cotyledon with independent maternal and fetal circuits, immune-complexed MSP1 transferred from maternal to fetal
circulation. MSP1 alone or with non-immune plasma did not transfer; pre-incubation with human plasma containing anti-
MSP1 was required. MSP1 bound to IgG was detected in the fetal perfusate. Laser scanning confocal microscopy
demonstrated MSP1 in the fetal villous stroma, predominantly in fetal endothelial cells. MSP1 co-localized with IgG in
endothelial cells, but not with placental macrophages. Thus we show, for the first time, antibody-dependent transplacental
transfer of an antigen in the form of immune complexes. These studies imply frequent exposure of the fetus to certain
antigens with implications for management of maternal infections during pregnancy and novel approaches to deliver
vaccines or drugs to the fetus.
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Introduction
Fetal exposure to allergens or molecules released by various
infections during pregnancy has been an area of intense study over
the past several decades. The immunological influences of early
exposure to these antigens may have profound effects on subsequent
susceptibility to allergy, atopy and risk of infection and disease later in
life [1]. How and when these antigens cross from maternal to fetal
environments may impact on the type of early immune responses and
why such responses appear to be restricted to certain antigens. In the
current study we use malaria as a paradigm to study the mechanisms
of transplacental transfer of antigens because the burden of infection
and disease occurs during pregnancy and early childhood.
The greatest susceptibility to malaria is during early childhood,
and most deaths due to malaria occur within the first 3 to 5 years
of life [2]. Considerable effort has focused on the genetic,
immunological, and environmental factors that influence this
susceptibility to malaria following birth. Prenatal factors affecting
the fetus in utero, however, have received comparatively little study
[3]. The fetus may be exposed to malaria because pregnant
women are at increased risk for infection as compared to
nonpregnant women [4]. Malaria infected erythrocytes preferen-
tially sequester in the placenta, producing an inflammatory
responses in the intervillous space, that likely contribute
to premature delivery or intrauterine growth retarda-
tion by mechanisms that remain poorly understood [5,6].
The observation that cord blood mononuclear cells from as many
as two thirds of newborns in malaria endemic areas produce
cytokines to malaria blood stage antigens [7,8] suggests malaria-
infected erythrocytes [9,10,11,12] and/or their soluble products
cross the placenta, where fetal lymphocytes are primed in utero
[13,14].
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stage antigens remain poorly understood. Congenital malaria is
uncommon and typically occurs in 10% or less of newborns of
malaria-infected women [9,11,15,16]. More likely soluble malaria
blood-stage antigens released upon rupture of infected placental
erythrocytes expose the fetus. Surprisingly, this possibility has
received little attention. Only a few studies have reported malaria
antigens in cord blood plasma from a small percentage of
newborns [11,13]. The limited ability to detect malaria blood
stage antigens with conventional immunoassays may be due to the
fact that the antigens are bound into immune complexes
[17,18,19]. As with many acute and chronic infections, immune
complexes (ICs) have been noted in asymptomatic and symptom-
atic individuals alike [19,20]. Immune complexes have been
detected in the placenta of malaria-infected women [17], but never
in cord blood. Surprisingly, little is known about the biochemical
nature of these ICs in malaria or what antigens are contained in
the complexes [21].
Previous studies have suggested transplacental transport of ICs,
most notably after immunization with tetanus toxoid [22,23], after
exposure to common allergens [24,25], and with administration of
non-human insulin in diabetic women [26,27]. These studies,
however, have never directly demonstrated transplacental transfer
of antigen bound to antibody. Here we hypothesize that malaria
blood stage antigens are transported transplacentally to the fetus as
ICs. To test this hypothesis we focused on Plasmodium falciparum
MSP1, which is a 195-kDa GPI- anchored protein on the
merozoite surface, representing the most abundant merozoite
surface protein [28]. We have previously shown frequent
fetal (cord blood) reactivity to MSP1 in a malaria
endemic area of Kenya [14]. MSP1 undergoes a series of
proteolytic cleavages during merozoite invasion of erythrocytes.
The final cleavage of the C-terminal 42kD portion of MSP1
(MSP142) releases a soluble fragment [29], with the most C-
terminal 19kD portion being retained on the surface, and later
carried into the erythrocyte during invasion [30]. Here we first
evaluate whether C-terminal fragments of MSP1 occur in cord
blood of offspring of malaria-infected women and whether they
are complexed with antibody. Next we study whether recombinant
MSP142, either alone or in the presence of anti-MSP1 antibody, is
transplacentally transported from the maternal to fetal circulation,
using a dual ex vivo perfusion model of the human placenta.
Materials and Methods
Human Plasma Samples
Eighteen paired samples of both maternal peripheral blood and
intervillous placental blood were obtained from P. falciparum -
infected women residing in a malaria holoendemic area in Kwale
District, Coast province, Kenya at delivery as described [11]. We
also examined cord blood from 20 women who did not have
evidence of malaria at delivery as well 15 cord blood samples from
newborns that delivered from healthy women in Cleveland, OH.
The maternal intervillous samples were obtained by cannulation of
the intervillous space with a 16-gauge needle through the basal
plate of the placenta. Cord blood from their offspring was collected
at delivery by cannulation of the umbilical vein proximal to the
point where the umbilical cord had been clamped. The presence
of P. falciparum infection was assessed by blood smear and/or real-
time quantitative PCR of maternal and cord blood samples as
described [11]. All samples were collected following written
informed consent of participating women. The Scientific and
Ethical Review Committees of the Kenyan Medical Research
Institute and the Institutional Review Board of Case Western
Reserve University approved the study. Pooled human plasma
containing anti-MSP1 immunoglobulin (endpoint titer to
1:256,000, by ELISA) was obtained from expired anonymous
units of blood collected at the Coast Province Blood Bank in
Kenya, all of which were negative for HIV and Hepatitis B
antibodies. The blood units were blood smear and PCR negative
for malaria. There was no MSP1 detected in the plasma,
and not complexed to immunoglobulin.
Measurement of MSP1 and MSP1 Immune Complexes in
Human Plasma and Placental Perfusate
A summary of the different assays used to detect MSP1 and
antibodies directed against MSP1 are summarized in Table 1.
Details of the assays are provided in the legend. All assays were
performed with a volume of 100ul using Immulon 4 ELISA plates
(Dynatech, Inc). Plates were then washed (PBS-0.05% Tween) and
Table 1. Assays used to detect MSP1 and antibodies to MSP1.
Assa No. Assay for
Material
Assayed Capture Ab (Ag) Detection Conjugate
1
a MSP1 Plasma/
perfusate
Affinity Purified Rabbit anti-MSP142
(1:1000 dilution)
Rat anti-MSP142 (1:1000 dilution) Goat a-rat alkaline
phosphatase (AP)
2
b Anti-MSP142 Plasma/
perfusate
rMSP142 (0.5 mcg/ml) Goat anti-human IgG (H+L)-AP (1:1000
dilution)
NA
3
c Biotinylated rMSP142
(bMSP142)
Perfusate Streptavidin (5mcg/ml) Rabbit aMSP142 Goat anti-rabbit
AP
4
d Anti-MSP1 bound to
bMSP142
Perfusate Streptavidin (5 mcg/ml) Goat anti-human IgG (H+L)-AP (1:1000
dilution)
NA
aPolyclonal anti-MSP142 was resuspended in carbonated-bicarbonated buffer (pH 9.6) and used to coat the ELISA plates as described in the materials and
methods section. As a standard, recombinant MSP142 was resuspended in the same media used for the test samples (i.e. plasma from N. American
subjects or perfusates) and added to the wells coated with anti-MSP142 at serial two-fold dilutions starting at 4 ng/ml. Sensitivity of the assay was
approximately 200 pg/ml.
bPlates were coated with rMSP142 in PBS.
cPlates were coated with streptavidin in PBS (Pierce Biotechnology Inc). Standards used for this experiment were bMSP142 or pooled human plasma containing anti-
MSP1 (25%) combined with bMSP142 as described in the text. The assay had a sensitivity ,175–200 pg/ml to detect the bMSP142 in the samples.
dPerfusate was added at 1:5 dilution to wells coated with streptavidin and incubated overnight at 4uC. Plates were washed thoroughly (6 times) with 0.1% Tween as
described in the text to remove any unbound antibody prior to adding goat anti-human IgG. Control experiments using MSP142 incubated with normal serum had
,0.15 OD and the mean+2 SD was subtracted from background described in figure 4.
doi:10.1371/journal.pone.0007986.t001
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test samples, which were incubated overnight at 4uC. The
authors generated the polyclonal rat and rabbit anti-
sera directed to MSP142. The sera, either rabbit or goat as
secondary antibodies, were obtained from Jackson ImmunoR-
esearch (West Grove, PA) and diluted in PBS to 1:1000 then
added to plates for 2h at 37uC. Following washes, 5-bromo-4-
chloro-3-indolyl phosphate/nitro blue tetrazolium alkaline phos-
phatase substrate solution (Sigma) was added and samples read by
a VERSAmax microplate reader (Molecular Devices, Sunnydale,
CA) at OD422 mm. Assay 1 measured MSP1 in plasma samples
and perfusate samples. Assay 2 measured anti-MSP142, not
bound to MSP142, in serum and perfusate samples from
the maternal and fetal circulation. Assay 3 measured
antigen-antibody complexes using biotinlyated rMSP142
(FVO allele [bMSP142]). Assay 4 measured antibodies
that bound bMSP142 in maternal and fetal circulation,
and anti-MSP142.
To dissociate antigen-antibody complexes we used an acid
dissociation protocol that has been used for several blood-borne
viruses [31,32]. Patient plasma samples or perfusate were either
diluted 1:3 in phosphate-buffered saline (PBS) (nondissociated
samples) or 1:2 in dissociation buffer (1.5 M glycine-HCl
[pH 2.0]). The antigen-antibody complexes were dissociated
for 30 minutes at 37uC and the reaction was stopped by addition
of 1 volume of neutralization buffer (1.5 M Tris-HCL [pH 9.7])
to achieve an end dilution of 1:3 for the sample. An additional 2
volumes of PBS were added for a final dilution of 1:5.
The sample was then immediately measured for MSP1 using
assay 1.
Measurement of Placental Alkaline Phosphatase (PLAP)
PLAP level was measured by use of a method of Kaneda et al
[33] and modified by Kwiek, et al [34]. The PLAP level in cord
and maternal blood was determined by interpolation from a
standard curve of purified human PLAP (Sigma) fit to quadratic
equation.
Placental Donors
Six human term placentas (gestational age 38–40 weeks,
placenta weight 648–918 g) were obtained from uncomplicated
singleton pregnancies delivered by caesarean section or vaginal
delivery. The local ethical review committee at the University of
Greifswald approved the study. Prior to delivery, women
gave written informed consent for use of their placentas
for the study.
Placenta Perfusion Model and Experimental Design
The dual circulation human placenta perfusion model [35]
included cannulation of the chorionic artery and the correspond-
ing vein of a suitable cotyledon, to perfuse the fetal side within
20 minutes of delivery (Figure 1A). The maternal side was
perfused by three blunted cannulas, which were introduced into
the intervillous space. The perfusion medium consisted of NCTC
135 (SIGMA-Aldrich, Steinheim, Germany) in Earl’s buffer (1:3,
v/v), 4% albumin (PAA Laboratories, Linz, Austria), 0.2% glucose
(Merck, Darmstadt, Germany), 1% dextrane 40 (Carl Roth,
Karlsruhe, Germany), 2,500 units/l heparin (Braun, Melsungen,
Germany), and 250 mg/l clamoxyl (Ratiopharm, Ulm, Germany).
To mimic the intrauterine conditions, two gas exchange devices
(Mera Silox-S 0.3, Senko Medical Instruments, Tokyo, Japan)
Figure 1. Perfusion model and experimental design. Panel (A) shows a diagram of the ex vivo placenta perfusion model as performed in the
study. Details of the assay are described in the methods section. Of note 3 probes on the maternal side cannulate the intervillous space and
on the fetal side one probe each cannulate the artery and vein. Panel (B) shows the experimental design for each of the 6 placentas studied.
A complete experiment comprised 3 phases. Phase I involved addition of rMSP142 to the maternal circulation with samples removed from the
maternal and fetal circulation every 30 minutes until the completion of the phase. Phase II and phase III involved addition of rMSP142 previously
mixed with 10% or 25% human plasma containing anti-MSP1 antibodies to form ICs. The perfusion pressures recorded throughout the experiment
are shown. A significant rise in perfusion pressure indicates poor placental flow of medium through the vasculature. If pressures rose too quickly as in
placenta 2, the experiment was terminated. Placenta 4 was terminated early to examine whether MSP142 without specific antibody could be detected
by immunohistochemistry in the villous stroma. Placenta 6 included MSP142 with 25% human plasma from individuals that have never resided in a
malaria endemic area and did not have a phase with lower serum concentrations.
doi:10.1371/journal.pone.0007986.g001
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nitrogen and 5% carbon dioxide, whereas an atmospheric gas
mixture was used for the maternal side. The flow rate was 12 ml/
min in the maternal and 4 ml/min in the fetal circuit, resembling
physiologic flow rates. The fetal arterial pressure was maintained
between 25 and 40 mmHg and the total perfusion volume in each
circuit was 140 ml.
At the beginning of all experiments, the placenta was perfused
for 30 minutes without return of the perfusate to the circulation
(open loop), to remove blood and metabolites from the two
placental circulations. This was followed by a closed-loop
perfusion (recycling of perfusate) for 60 min to equilibrate the
placenta and to identify leaks or shunts between maternal and fetal
perfused circulation. Experiments were terminated for fetal
perfusion pressure above 50 mmHg, for loss of perfusate.4 ml/
h from the fetal circulation, and for cases of mismatch of maternal-
fetal circulation as measured by the antipyrine permeability (i.e.
lower levels of permeability, ,0.04 ml6min
216g
21, Table 2).
After the initial equilibration of the placenta for 60 min in
which the medium was exchanged in both circuits, the actual
experiment consisted of three phases lasting 120 min each
(Figure 1B). All media were mixed one day before the experiment
and incubated overnight at room temperature. Between experi-
mental phases, a 30 min ‘‘wash-out’’ using open perfusion with
fresh media was performed on both the maternal and fetal
circulations, to wash out any antigen and/or antibody. For phase
I, rMSP142 was added to the maternal side only at a final
concentration of 1 mg/ml, and both the maternal and fetal
perfusates were sampled every 30 minutes as described above. For
phase II fresh maternal perfusate was modified to include 1 mg/ml
MSP142 and 25% immune plasma containing anti-MSP1
antibodies, to form ICs described above. For phase II the fetal
perfusate medium contained 25% fetal calf serum (FCS, without
MSP142) to maintain a similar oncotic pressure for fetal and
maternal circulations. For phase III, the maternal circulation
contained 1 mg/ml MSP142 and 10% immune plasma containing
anti-MSP1 antibodies, and the fetal circulation contained 10%
FCS without MSP142. (Of note, phase II and phase III were
reversed for experiment 5). Two control experiments were
performed, consisting of i) perfusion with MSP142 in the absence
of antibodies, with early termination to examine histological
sections (No. 4) and ii) perfusion with MSP142 preincubated with
25% plasma from individuals who had never traveled to malaria
endemic areas and therefore lacked anti-MSP1 antibodies (No. 6).
Initially, experiments with placentas Nos. 1 and 2 were terminated
early because of an increase in fetal perfusion pressure following
addition of immune plasma (phase 2). Experiment No. 2 had to be
terminated early. In subsequent experiments plasma was first
dialyzed against phosphate buffer saline (PBS) with a MW cut-off
of 25 kD, which eliminated the increase in perfusion pressures
during the course of the experiment. Data on viability as assessed
by consumption of glucose and production of lactate and human
chorionic gonadotropin (hCG) during the course of the experi-
ments as well as permeability as measured by antipyrine (0.4 mM),
creatinine (1.3 mM) and erythropoietin (1.0 ug/ml), which were
also added in all three experimental phases in the maternal circuit,
were consistent with previous studies (Table 2).
Sample Collection
One ml aliquots were obtained from both the fetal and maternal
circulations at the beginning, and every 30 minutes thereafter.
Prior to removal of medium the volumes were checked in each
reservoir for evidence of perfusate leak from the maternal to the
fetal circulation. Placental tissue samples were randomly taken
from an unperfused area before the beginning of each experiment
and from the perfused cotyledon at the completion of the whole
experiment. Samples were immediately cryopreserved or fixed in
4% paraformaldehyde and embedded in paraffin.
Assays for Glucose, Lactate, Creatinine, Antipyrine, hCG
and Erythropoietin Biometrical Evaluation
Glucose, lactate, creatinine, antipyrine and hCG concentrations
were measured as described recently [36]. Erythropoietin was
measured using the Human Erythropoietin Quantikine IVD ELISA
Kit (R&D Systems, Minneapolis, USA) according to the supplier’s
instructions.Permeabilityofantipyrineandcreatininewascalculated
according to the equation P=Cfet/(weightcot6[AUCmat2AUCfet])
with Cfet to be the concentration in the fetal circuit at the end of
perfusion, AUCmat the area under the concentration-time curve
(AUC) in the maternal circuit, AUCfet the AUC in the fetal circuit,
and weightcot the wet weight of the cotyledon [37]. The hCG release
was calculated as described [38]. Means 6 standard deviations (SD)
are given. Sample statistics were done using the Wilcoxon test.
Immunohistochemistry
Paraffin fixed sections of the placenta were sectioned
at 2 mm thickness, then deparaffinized and rehydrated. Sec-
tions were boiled for 10 min with citrate buffer (pH 6.0, 1.8 mmol/L
citric acid, 12.2 mmol/L sodium cirate) before blocking with 5% fetal
calf serum for 2 hours. MSP142 was detected using 1:50 dilution of rat
anti-MSP142 polyclonal Ab (the same antibody used for antigen
capture assay in Table 1) followed by a AlexaFluor 488
conjugated goat anti-rat secondary antibody (1:200, Invitrogen,
Carlsbad, Ca, USA). A mouse anti-CD68 (mAb Kp1, 1:25, Santa
Table 2. Permeability of antipyrine, creatinine, erythropoietin and viability characteristics of perfused placentas used in the studya.
Protocol 1
b 234 56
glucose consumption (mmol6min
216g
21) 0.336
c60.106 0.18660.109 0.18960.062 0.369 0.26760.010 0.38560.069
lactate production (mmol6min
216g
21) 0.46160.100 0.38760.097 0.49060.062 1.151 0.41860.106 0.80860.289
antipyrine permeability (ml6min
216g
21) 0.05460.028 0.0860.002 0.16660.064 0.129 0.12060.029 0.16960.024
creatinine permeability (ml6min
216g
21) 0.02160.005 0.01360.003 0.04160.004 0.047 0.03860.009 0.04960.001
erythropoietin permeability (ml6min
216g
21) 0.00 0.00 0.00 0.00 0.00 0.00
hCG release (mU6min
216g
21) 69. 17 78.57 31.10 307.66 102.03 139.84
aAll values shown fall within the range of values for previous placental perfusion studies without any experimental interventions [38].
bExperiment number (each represents a complete perfusion experiment with different placentas.
cMeans6SD are shown for all phases of the experiment. For placenta 4 only one phase is shown.
doi:10.1371/journal.pone.0007986.t002
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PECAM-1 (1:200, Santa Cruz Biotechnology Inc.), followed by an
AlexaFluor 568 conjugated goat anti-rabbit and anti-mouse secondary
antibody (1:100, Invitrogen), respectively, were used for staining of
macrophages/Hofbauer cells (anti-CD68) and endothelial cells (anti-
CD31). Nuclear counterstaining was performed using TOTO-3-iodide
(Invitrogen) added to the mounting medium (dilution 1:2000,
DakoCytomation, Glostrup, Denmark). Co-localization of markers
was examined using a laser scanning confocal microscope.
Immunohistochemistry was performed on samples from
all 6 placentas used.
Statistical Analysis
Comparisons of MSP142 levels were performed by Student’s t-
test of log-transformed values. When appropriate, paired t-tests
were performed (i.e. Figure 2B).
Results
Circulating MSP1 and Immune Complexes in Cord Blood
Soluble MSP1 was present in the blood of pregnant women
infected with malaria and in cord blood of their newborns
(Table 3). The presence of MSP1 in cord blood is unlikely to have
occurred by admixture with maternal blood at delivery. We
measured the levels of placental alkaline phosphatase (PLAP) in
both maternal intervillous and cord blood in an initial group of 5
paired samples. PLAP is produced in high levels by the
syncytiotrophoblast (STB) and released solely into the maternal
compartment of the placenta [33], and thus is used as a marker of
maternal-fetal transfusion during the peripartum period
[11,33,34]. PLAP levels were undetectable in 4 of 5 cord blood
samples and low in the remaining one (Table 3). We cannot
exclude the possibility that MSP142 detected in cord
blood for case 3 may have occurred because of
admixture from maternal blood. By contrast PLAP levels
were markedly higher in maternal intervillous blood, indicating
little or no peripartum maternal to fetal transfusion. There was no
correlation between levels of MSP1 in maternal and cord blood
(r
2=0.13, p=0.19). Thus the MSP1 detected in cord blood was
unlikely to have resulted from admixture with maternal blood.
We next examined whether antibody bound to MSP1 impairs
its detection by ELISA (i.e. assay 1, see table 1). Addition of 1 ug/
ml of purified rMSP142 in PBS with varying concentrations of
pooled plasma containing anti-MSP1 antibodies from malaria
exposed (but not actively infected) individuals reduced detection of
antigen in a dose-dependent fashion (Figure 2A). This suggests
formation of antigen-antibody complexes. Dissociation of these
complexes with dissociation buffer partially restored the ability to
detect MSP1. Of note, dissociation buffer treatment of rMSP142
without antibody resulted in partial reduction in antigen detection,
probably due to denaturation of some epitopes.
In addition to the 5 initial paired maternal and cord blood
samples, we examined an additional 13 paired maternal samples
infected with malaria (5 intervillous and 8 peripheral
venous blood) at delivery, to assess whether MSP1 may be
complexed to antibody, thereby impairing its detection. Without
treatment of samples with dissociation buffer, MSP1 was detected
in 5 of 13 cord blood plasma samples (Figure 2B); following
treatment with dissociation buffer, MSP1 detection increased to 12
of 13 cord samples (Figure 2B). Of note, the 5 cord blood
samples shown in Table 3, acid dissociation also
enhanced detection of MSP142 in 4 samples (also shown
in Figure 2B). MSP1 was detected in maternal samples in 7 of 13
individuals before, and in all samples following treatment with
dissociation buffer (data not shown). There was no correlation
between MSP1 levels in paired maternal and cord blood. Free
antibody to MSP142 of varying titers was present in all 18 paired
maternal cord blood samples (data not shown). There was no
relationship between maternal anti-MSP142 antibody
levels and the presence and levels of MSP142 in cord
blood, either before or after acid dissociation (data no
shown). In cord blood of malaria negative women at delivery, 1
Figure 2. Detection of MSP142 complexed to antibodies in cord blood of plasma from Kenyan newborns. Adding varying
concentrations of plasma containing anti-MSP142 with recombinant MSP142 impaired detection of MSP142 using an antigen capture ELISA (assay 1)
indicating formation of ICs. Dissociation of ICs partially restored the ability to detect MSP142 (A). Panel (B) shows the presence of MSP1 in cord blood
plasma of offspring of malaria infected Kenyan women detected by ELISA (assay 1) before and after dissociation of ICs (connecting lines). Each point
represents the average of two independent assays run on the same sample. Variation for the repeat assay for each sample was ,16%. The p value
shown in figure 2B comparing samples before and after acid dissociation was performed was using a paired t-test.
doi:10.1371/journal.pone.0007986.g002
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MSP1 before and after acid dissociation respectively, indicating
the persistence of antigen even after the parasitemia is cleared
(Figure 2B). No MSP1 was detected in cord blood from North
American newborns. Thus, MSP1 is frequently found in malaria-
infected women’s peripheral and/or intervillous placental blood
and in cord blood from their offspring. MSP1 is often complexed
to antibody.
Transplacental Transport of MSP142 Using the Ex Vivo
Placenta Perfusion Model
Since none of the cord blood samples identified as containing
MSP1 had evidence of malaria parasites (blood smear and PCR
negative) at delivery, we postulated that soluble MSP1 crosses
transplacentally from maternal to fetal circulation during gesta-
tion. To test this hypothesis we used a dual ex vivo placental
perfusion model (Figure 1A) to examine whether transplacental
transfer of soluble MSP1 can occur alone or in complex with
specific antibodies. Addition of rMSP142 alone to the maternal
circulation failed to show transplacental antigen transfer (i.e. no
MSP1 was detected in the fetal perfusate within the first 2 hours in
any experiment, Figure 3). Transplacental transfer of MSP142
occurred only when the antigen was previously incubated with
plasma containing specific anti-MSP1 to form antigen-antibody
complexes (described in Figure 2A), as shown for placentas Nos. 2,
3 and 5 (Figure 3). Transplacental transport increased with higher
concentrations of plasma (Nos. 3 and 5). There was no
transplacental transport of MSP1 mixed with plasma that did
not contain specific antibodies to MSP1 (No. 6). Transplacental
transport occurred quickly, in that antigen was detected
30 minutes following addition of antigen plus anti-MSP1 antibody
to the maternal circulation, although the time to peak levels of
MSP142 detection varied among perfused placentas. Between 0.3
and 0.9 percent of total MSP142 was transferred from maternal to
fetal circulation during the course of the experiments using
modifications of the permeability equations. Quantification of
antigen by ELISA, however, can be affected by the presence of IC,
as well as partial denaturation of antigen with dissociation buffer.
To further demonstrate specific transplacental transfer of MSP142
and absence of leaks in the placenta, 1 ug/ml of erythropoietin, a
protein of similar size (34 kD), was added to the maternal
perfusate in each phase of all experiments. Erythropoietin was
never detected in the fetal perfusate (Table 2). This is consistent
with results previously shown in this system [39]. Thus
transplacental transport of rMSP142 is selective and requires
specific antibody.
As evidence of transplacental transfer of MSP142 occurring in the
form of ICs, we noted that more MSP1 in fetal perfusate was
detected followingtreatmentwithdissociationbuffer,indicatingthat
at least some MSP1 was bound to antibody (Figure 3). We also
directly observed human IgG antibody bound to rMSP142 in the
fetal perfusate. This was accomplished by using biotinylated
rMSP142 in the experiment with placenta No. 5 (Figure 4).
Biotinylation of rMSP142 permitted a modified MSP142 ELISA
(i.e. assay 4, table 1) whereby high affinity binding to streptavidin
followed by a more stringent washing protocol allowed removal of
non-specific binding of human IgG. Of note, a similar assay was
performed on non-dissociated samples with subclass-specific IgG.
The predominant antibodybound to bMSP142 in the fetal perfusate
was IgG1 and some IgG3, but no IgG2 or IgG4 (data not shown).
Free anti-MSP1 antibody was also detected in the fetal
circulation after addition of immune plasma in the presence of
antigen to the maternal circulation (Figure 3), but levels were
lower compared to that in the maternal circulation. This suggests
that either free specific antibody crosses the placenta or dissociates
from antigen once in the fetal circulation.
Immunolocalization of MSP1 in the Placenta
We obtained placental biopsies prior to and following perfusion
for every placenta. Immunohistochemical localization of MSP142
in the placental villous stroma was not detectable in the absence of
specific antibody to MSP1 (Figure 5B), or with non-specific
antibody (not shown). By contrast in all experiments in which
transplacental transfer of MSP142 occurred in the presence of anti-
MSP1, MSP142 was detected in the placental villous stroma
(Figure 5 D). Placental biopsies obtained prior to perfu-
sion (Figures 5A and 5C, controls) showed slight non-
specific staining of STM with the rat anti-MSP1 Ab, but
no detection within the placental villous stoma. Within the
stroma MSP142 did not co-localize with placental macrophages
(i.e. CD68 positive Hofbauer cells, Figure 6), but accumulated
adjacent to or within endothelial cells of fetal vessels (i.e. co-
localization with CD31 Figure 7, upper and lower panels).
Importantly, MSP142 co-localized with human IgG in and around
the endothelial cells of fetal vessels (Figure 8).
Discussion
There is considerable evidence that dietary antigens [24,40],
allergens [25,41,42,43] and parasite antigens [11,44] transfer from
the maternal to fetal environment in utero. This presumably occurs
transplacentally or by the fetus swallowing or inhaling antigens in
the amniotic fluid. However, the frequency, mechanisms, and
selectivity of antigen transfer are poorly understood. Cord blood
from offspring of malaria-infected women often acquires T and B
cell responsiveness to malaria blood stage antigens, thus raising the
question as to how the fetus becomes regularly exposed to these
antigens. Generally the placenta provides an effective barrier in
preventing exposure of the developing fetus to the harmful effects
of pathogens or circulating proteins in the maternal circulation,
except those required for fetal growth and development through
active transport mechanisms. Occasionally maternal-fetal micro-
transfusions occur during pregnancy resulting in congenital
malaria [11], however the frequency of such infection is too low
to account for the proportion of newborns who show immune
priming to malarial antigens. This suggests that soluble products of
malaria blood stage infection must cross the placenta with some
frequency. Here we show that the most abundant malaria blood
Table 3. MSP1 is present in cord blood of women with
malaria at delivery.
Case Cord Blood
Maternal Peripheral and/or
Intervillous blood
a
MSP1 (pg/ml) PLAP
b (ng/ml) MSP1 (pg/ml) PLAP (ng/ml)
1 272 ,20 936 361
2 431 ,20 592 1,107
3 297 37 669 232
4 389 ,20 1,256 1,845
5 241 ,20 520 688
aAll mothers were malaria infected at the delivery as shown by either PCR and/
or blood smear. Cases 1–4 represent intervillous blood samples and
case 5 maternal peripheral blood.
bPlacental alkaline phosphatase.
doi:10.1371/journal.pone.0007986.t003
Transplacental MSP1 Transfer
PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7986stage antigen, MSP1 [28], is present in cord blood of offspring of
malaria-infected women. The dissociation of ICs in cord blood
samples markedly increases the proportion with detectable MSP1.
Thus MSP1 may be transported across the placenta bound to
antibody.
The placenta has a receptor-mediated capacity to actively
transport immunoglobulin G (IgG) from the maternal to fetal
circulation [23,45,46]. Transplacental transport of IgG begins in
the second trimester and increases throughout gestation, with most
transport occurring late in pregnancy [47]. Prior studies suggest
that IgG may act as a vehicle to carry proteins across the placental
barrier from the maternal to the fetal side. Normally human
insulin does not cross the placenta [48]. Earlier studies from
pregnant diabetic women treated with animal insulin, however,
noted that some offspring with macrosomia also had animal
insulin in their cord blood [26,27]. Antibody production can be
stimulated by animal insulin, and of note cord blood levels of
animal insulin were directly related to maternal levels of insulin
antibodies. This suggests a role for insulin bound to antibody in
transplacental transport. Another study examining transplacental
transport of tetanus toxoid (TT) antibodies using the ex vivo
placental perfusion model reported tetanus antigen in both the
maternal and fetal perfusate. The ratio of TT antigen to TT-
specific antibody in the maternal perfusate closely correlated to
that observed in the fetal circulation, suggesting coupling of
antigen transfer to the specific transport of antibody [22,23].
Immune complexes with cat allergens have also been noted in cord
blood [41,42].
Using the same ex vivo placenta perfusion model, we show that
transplacental transfer of rMSP142 required the presence of
Figure 3. Measurement of MSP142 and free anti-MSP1 antibodies in maternal and fetal circulation with the placental perfusion
model. The levels of MSP1 in the fetal perfusate were measured before (nondissociated) and after treatment with dissociation buffer (dissociated)
during the 3 phases of the experiment. The differences in levels of MSP142 detected in the fetal perfusate between phases II and III
(placentas 3 and 5) correlated with percentage of plasma containing anti-MSP1 antibodies added to the maternal compartment.
Each point represents the mean value performed in triplicate. The variation between replicate samples was ,10%. Assay 1 was used to measure
free MSP1 and assay 2 for free anti-MSP1 antibodies (see table 1).
doi:10.1371/journal.pone.0007986.g003
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MSP1 following dissociation of the ICs, direct detection of human
IgG complexed to MSP142 in the fetal perfusate, and co-
localization of MSP142 with human IgG in the endothelium of
the fetal capillaries suggest that antigen complexed with antibody
crossed the placenta to the fetal circulation. Free antibody to
MSP142 was also found in the fetal circulation; whether this
represents transplacental transport of antibody alone, dissociation
of IC after transport to the fetal circulation, or both, is unclear.
The ability to detect MSP142 in the maternal plasma samples or
maternal perfusate without acid dissociation may represent
excess free antigen relative to specific antibody. The presence of
free MSP142 in the fetal and maternal perfusate may also represent
recognition of epitopes on MSP142 by the rat and rabbit antisera
that are not bound by specific human antibodies. Of note there
was a decrease in the levels of MSP142 and anti-MSP1 in
the fetal perfusate with time suggesting possible protein
catabolism or binding within the fetal circulation,
although the mechanisms remain unclear.
The exact mechanism by which IgG facilitates the transplacen-
tal passage of a particular antigen is unclear. It has been postulated
that the syncytiotrophoblast (STB) takes up ICs by micropinocy-
tosis, which then accumulate in the endosomal compartment. The
lower pH in endosomes facilitates the binding of IC to MHC-class
I related I Fc receptors of the neonate (FcRN). Immune complexes
that remain bound to FcRN do not undergo degradation. The
endosomes are then recycled to the basolateral surface of the STB
where the higher pH releases the ICs from FcRN. If antigen
dissociates from the antibody while in the endosome it is shunted
to the lysosome for degradation [46]. Thus survival of antigen in
the endosome depends on its affinity to antibody at acidic
Figure 4. The presence of human IgG complexed to rMSP142 in
fetal perfusate. rMSP142 was biotinylated (bMSP142) and thus the
configuration of ELISA differed from that described in Fig. 3, e.g. streptavidin
was used to capture bMSP142 followed by anti-human IgG (assay 3, see
table 1, squares). Nondissociated MSP142 levels were also measured (assay 2,
see table 2, triangles). The assay was performed for placenta 5. Values
indicate means6SD of replicate assays (N=3). Asterisks indicate significant
differences from P,0.05 to P,0.001 between samples. Assay 3 was used
to measure non-dissociated bMSP142 and assay 4 for human IgG
complexed to rMSP142 (see table 1).
doi:10.1371/journal.pone.0007986.g004
Figure 5. Immunohistological localization of MSP142 in the villous stroma before and after perfusion. Panel (A,C) show before and
panels (B,D) after perfusion with MSP142 in the absence of anti-MSP1 (No. 4; A,B) and following addition of anti-MSP1 (No. 5; C,D). The
syncytiotrophoblastic membrane (STM) is shown in light green with strings of nuclei (blue). MSP142 has intense green staining only in the villous
stroma of No. 5 following perfusion (indicated by arrows, D). Panel E shows a hematoxylin and eosin stained section from the same
placenta for reference. The labels are: IVS – intervillous space, FC – fetal capillary, STM - syncytiotrophoblastic membrane, FVS –
fetal villous stroma. All sections are at 2006magnification. The staining with pre-bleed sera from rats used for making the anti-rMSP142
polyclonal sera was identical to that shown in panels A and C (not shown).
doi:10.1371/journal.pone.0007986.g005
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the endosomal transit time.
Following deposition of antigen and antibody in the basolateral
surface of STB, they are somehow transported through the villous
stroma, perhaps by passive diffusion, until reaching the endothelial
cells where again a specific transport system mediates transendothe-
lial cell transfer to the fetal circulation. The fetalendothelial cells are
too tightly apposed to each other to allow passive diffusion of such
large molecules [49]. The exact mechanisms by which human IgG,
much less antigen complexed to antibody, passes through fetal
endothelial cells remain unknown. The FcRN may also mediate
transfer, however FcRN is only occasionally or weakly expressed in
fetal vessel endothelium in the placenta [50,51,52]. Another
receptor in fetal endothelial cells, FccRIIb, has been found to
colocalize with human IgG suggesting a role in its transport [53].
Placental macrophages or Hofbauer cells in the villous stroma
expressing FccRI, RII, and RIII, are thought to bind ICs, forming
part of the protective barrier of the placenta between the mother
and the fetus [54,55]. Using laser scanning confocal microscopy, we
co-localized the malaria antigen within and adjacent to endothelial
cells, but not in the STB or with Hofbauer cells. The failure to
observe malaria antigen in STB may simply reflect the rapid
transport of antibody and antigen across this membrane. However,
the lack of co-localization of the MSP142 with Hofbauer cells is not
compatible with the notion that these cells capture ICs (or at least,
the ICs formed by MSP142). A number of questions remain as to
exactly how antigens cross to the fetal circulation. Is there
intracellular dissociation of the IC from FcRN in STB and/or
Figure 6. MSP142 does not co-localize with placental macrophages (Hofbauer cells). Panel (A) shows MSP142 localizes to fetal vascular
structures (green staining, indicated by green arrows) and not with placental Hofbauer cells (CD68 positive cells, red staining indicated by red arrow).
Panel (B) shows a greater magnification of the villous stroma. The results are shown for placenta 3. No co-localization of CD68 positive cells with
MSP142 was observed for all 4 placentas examined. The left had panel at 4006and right at 8006.
doi:10.1371/journal.pone.0007986.g006
Figure 7. MSP142 co-localizes with fetal endothelial cells following perfusion. MSP142 (green staining) co-localizes with CD31 (PECAM-1, red
staining) indicating its presence in and around the fetal vascular endothelial cells (upper and lower panels for placentas 1 and 5 respectively). Similar
co-localization was observed for placentas 2 and 3 (not shown). The upper panels are at 4006and lower at 2006magnification.
doi:10.1371/journal.pone.0007986.g007
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mechanisms into the fetal circulation? Alternatively, whether there
is ‘‘trapping’’ of ICs in the villous stroma and passage of excess ICs
intothe capillaries, with subsequent releaseinto fetal blood, needsto
be addressed in future studies.
Notable was that only some fetal endothelial cells demonstrated
immunohistochemical localization of MSP142 and/or IgG. It is
possible that there may be variation in the circulation within the
perfused placenta such that some endothelial cells may have more
rapidly transported the antigen and/or IgG, while others did more
slowly, resulting in heterogeneity of immune localization.
Pregnant women often become infected and ICs can form
during the course of these infections. If ICs cross to the fetal
circulation as easily as suggested in the current study, the
cumulative effect on the fetus would presumably be detrimental.
Thus there is likely some selectivity in the transplacental trafficking
of IC, perhaps based on IC structure. Immune complexes vary
depending on the valency of bound ligands. A recent study showed
that multimeric IC that bind to FcRN in the endosomes of
dendritic cells are targeted to lysosomes and undergo degradation,
whereas monomeric IC do not undergo such a fate [56]. Whether
a similar mechanism occurs in the STB is unclear. It is conceivable
that MSP142 forms monomeric or dimeric IC because this
molecule has few B cell epitopes [57]. By contrast other malaria
antigens with multiple B cell epitopes may form multimeric IC that
rarely transfer transplacentally.
Placental malaria can cause a number of pathologic changes in
the placenta [6] and these changes can reduce transplacental
transfer of specific IgG immunoglobulins [58]. In addition
repeated malaria infection often stimulates polyclonal production
of non-specific IgG [58]. These factors may also affect the amount
and timing of transplacental transfer ICs to the fetus.
Thus, the wealth of studies to date, especially in humans,
demonstrate that specific receptor-mediated transfer of IgG
immunoproteins is regulated by the transporter/receptor ex-
pression not only on the syncytiotrophoblast but also on fetal
endothelium and stromal tissue s .F u r t h e r ,t h eF ce n do ft h e
immunoglobulin defines the ability to be transferred [59], and
growing evidence suggests that antigens bound to these
immunoglobulins, e.g., malaria proteins, may frequently be
transferred through the placenta and extraembryonic mem-
branes tothefetus,muchlike the ‘‘Trojanhorse’’ofthe past. This
exposure could have dramatic effects on the fetal immune
response with several possible outcomes. Some offspring may
acquire protective immune responses that persist into infancy.
Alternatively, the fetus may acquire immune tolerance, either by
anergy or deletion of T cell clones or the development of
regulatory T cells [60,61]. These latter responses may increase
the infant’s susceptibility to malaria infection and disease.
Whether the infant acquires protection or tolerance may depend
on the timing, or the amount and type of antigen to which the
fetus is exposed during gestation. An understanding of these
outcomes would have important implications as to when, and
how much, malaria chemoprophylaxis should be administered
during pregnancy in endemic areas.
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